Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 56Breast Neoplasms 49Ovarian Neoplasms 31Triple Negative Breast Neoplasms 27Endometrial Neoplasms 25Lung Neoplasms 24Fallopian Tube Neoplasms 22Neoplasm Metastasis 21Squamous Cell Carcinoma of Head and Neck 19Parkinson Disease 4, Autosomal Dominant Lewy Body 18Neoplasms 14Esophageal Squamous Cell Carcinoma 12Esophageal Neoplasms 12Carcinoma, Ovarian Epithelial 9Stomach Neoplasms 8Head and Neck Neoplasms 8Colorectal Neoplasms 8Carcinoma 7Adenocarcinoma Of Esophagus 7Peritoneal Neoplasms 6Adenocarcinoma 6Uterine Cervical Neoplasms 5Melanoma 5Oropharyngeal Neoplasms 4Cholangiocarcinoma 4Carcinoma, Transitional Cell 4Urinary Bladder Neoplasms 3Small Cell Lung Carcinoma 3Recurrence 3Pancreatic Neoplasms 3

Interventions

Paclitaxel 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Cervical Cancer × Paclitaxel × 90 days × Clear all
NCT07168200 2026-04-15

A Phase III Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy Versus Placebo Combined With Concurrent Chemoradiotherapy for the Treatment of Locally Advanced Cervical Cancer

Shanghai Shengdi Pharmaceutical Co., Ltd

Phase 3 Recruiting
720 enrolled
Gynecologic

Advanced Cervical Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡